NEOD001

An Investigational Agent for the Treatment of

AL Amyloidosis

Prothena Corporation is investigating new treatments for amyloidosis. Its lead candidate, NEOD001, is a humanized monoclonal antibody, which preclinical studies suggest may bind and neutralize amyloid in amyloid light chain (AL) amyloidosis. Unlike existing therapies, NEOD001 is specifically designed to target this form of amyloid, which is believed to contribute to organ dysfunction in patients with this disease. NEOD001 has investigational orphan drug status in the United States and Europe.



NEOD001 monoclonal antibody targets a binding site (epitope) unique to misfolded light chain protein

UNDERSTANDING AMYLOIDOSIS

Systemic amyloidosis is a family of rare progressive diseases in which abnormally folded proteins clump together to form aggregates, known as amyloid, that can accumulate and cause damage in organs and tissues.

AL amyloidosis is the most common form of systemic amyloidosis. In AL amyloidosis, plasma cells, a part of the immune system, overproduce an antibody fragment called light chain protein in an abnormal form that misfolds. The resulting amyloid accumulates in one or more organs, where it can disrupt normal functioning. The heart and kidneys are often sites of amyloid deposition in this disease.



Organs where amyloid commonly accumulates

There are currently no approved therapies for AL amyloidosis. To limit production of amyloid, patients with AL amyloidosis are often treated with chemotherapeutic drugs to reduce the plasma cells that produce the abnormal light chain. Eligible patients may also receive organ and/or autologous stem cell transplants. These treatment strategies are intended to reduce production of new abnormal light chain, but no approved treatment directly targets amyloid already formed. The drugs commonly used today to treat AL amyloidosis were originally developed to treat cancers, whereas NEOD001 is a humanized monoclonal antibody specifically designed to target amyloid in this disease.

NEOD001: ONGOING PHASE 1 CLINICAL TRIAL

NEOD001 is currently in Phase 1 clinical testing in patients with AL amyloidosis (Clinicaltrials.gov Identifier NCT01707264). Participating patients receive intravenous NEOD001 once every 28 days; if the dose level is safe and well-tolerated, subsequent dose groups will receive a higher dosage at the start of the next 28-day period. The dose level is escalated until the maximum tolerated dose, or recommended dose for Phase 2/3, is identified.

prothena™



The primary objective of this ongoing Phase 1 clinical trial is to evaluate the safety and tolerability of NEOD001 in patients with AL amyloidosis and to determine the appropriate dose levels for further testing in order to initiate a Phase 2/3 study. In Phase 2/3, additional patients will be eligible to participate, and the primary objectives will be to establish the safety and effectiveness of NEOD001 for the treatment of patients with AL amyloidosis.

Patients are being recruited and treated at the following centers in the United States:

Boston University School of Medicine
Boston, Massachusetts 02118
Principal Investigator: David C Seldin, MD, PhD
Contact: Anthony Shelton
617-638-5612
anthony.shelton@bmc.org
Contact: Stephen Lo
617-638-8274
stephen.lo@bmc.org

Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania 19104
Principal Investigator: Brendan Weiss, MD
Contact: Scott Weber, BA
215-349-8913
scott.weber@uphs.upenn.edu

Karmanos Cancer Institute
Detroit, Michigan 48201
Principal Investigator: Jeffrey A Zonder, MD
Contact: Christiane Houde, BS, CCRP
313-576-9381
houdec@karmanos.org

Mayo Clinic
Rochester, Minnesota 55905
Principal Investigator: Morris A Gertz, MD
Contact: Ann Birgin, CRA
507-284-8828

Memorial Sloan-Kettering Cancer Center
New York, New York 10065
Principal Investigator: Heather Landau, MD
Contact: Heather Landau, MD
212-639-8808
landauh@mskcc.org
Contact: Hani Hassoun, MD
212-639-3228

Stanford University Cancer Center
Palo Alto, California 94305
Principal Investigator: Michaela Liedtke, MD
Contact: Ying Hao, PhD
650-723-0646
yhao@stanford.edu

Tufts Medical Center
Boston, Massachusetts 02111
Principal Investigator: Raymond Comenzo, MD
Contact: Jodi Jensen, RN
617-636-5558
jjensen@tuftsmedicalcenter.org

Study Director Theresa Neumann, PhD
theresa.neumann@prothena.com

For preliminary results from the Phase 1 trial, see **poster #PB-48, ISA 2014** or **www.prothena.com**

Talk with your doctor to determine if participating in a clinical trial could be right for you. For more information, please visit:

http://www.prothena.com/
http://clinicaltrials.gov/show/NCT01707264
http://www.amyloidosis.org/
http://www.amyloidosissupport.org/

ABOUT PROTHENA

Prothena Corporation plc is a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, including AL and AA amyloidosis. Onclave Therapeutics Limited, a wholly owned subsidiary of Prothena, is conducting the Phase 1 clinical trial of NEOD001.

prothena™